Selecta Biosciences Stock Price, News & Analysis (NASDAQ:SELB)

$9.27 -0.06 (-0.64 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$9.27
Today's Range$9.11 - $9.54
52-Week Range$8.40 - $24.02
Volume234,488 shs
Average Volume205,477 shs
Market Capitalization$207.06 million
P/E Ratio-2.99
Dividend YieldN/A
Beta-7.16

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences logoSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400

Debt

Debt-to-Equity Ratio0.32%
Current Ratio9.48%
Quick Ratio9.48%

Price-To-Earnings

Trailing P/E Ratio-2.99032258064516
Forward P/E Ratio-4.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.08 million
Price / Sales25.63
Cash FlowN/A
Price / CashN/A
Book Value$3.02 per share
Price / Book3.07

Profitability

Trailing EPS($3.10)
Net Income$-36,210,000.00
Net Margins-1,918.59%
Return on Equity-100.06%
Return on Assets-61.41%

Miscellaneous

Employees66
Outstanding Shares22,340,000

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences Inc (NASDAQ:SELB) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.22. Selecta Biosciences had a negative net margin of 1,918.59% and a negative return on equity of 100.06%. View Selecta Biosciences' Earnings History.

Where is Selecta Biosciences' stock going? Where will Selecta Biosciences' stock price be in 2018?

2 equities research analysts have issued 1-year price targets for Selecta Biosciences' shares. Their predictions range from $28.00 to $30.00. On average, they expect Selecta Biosciences' share price to reach $29.00 in the next year. View Analyst Ratings for Selecta Biosciences.

What are Wall Street analysts saying about Selecta Biosciences stock?

Here are some recent quotes from research analysts about Selecta Biosciences stock:

  • 1. Canaccord Genuity analysts commented, "We expect the combination dosing to provide rapid, sustained SUA lowering similarly to what has been seen for the combination SEL-212 + SVP dosing in the ongoing Phase 2 trial." (1/18/2018)
  • 2. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (1/10/2018)
  • 3. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Who are some of Selecta Biosciences' key competitors?

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the folowing people:

  • Omid Farokhzad M.D., Chairman of the Board (Age 48)
  • Werner Cautreels Ph.D., President, Chief Executive Officer (Age 64)
  • John H. Leaman M.D., Chief Financial Officer, Principal Accounting Officer, Head of Corporate Strategy and Treasurer (Age 45)
  • Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development (Age 49)
  • Takashi Kei Kishimoto Ph.D., Chief Scientific Officer (Age 57)
  • David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary (Age 51)
  • Dmitry Ovchinnikov, Managing Director, SelectaRUS, LLC
  • Earl Sands M.D., Chief Medical Officer (Age 59)
  • Carl L. Gordon Ph.D., Director (Age 52)
  • Edwin M. Kania Jr., Director

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Who owns Selecta Biosciences stock?

Selecta Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (1.10%) and Hamilton Lane Advisors LLC (0.24%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Earl Sands, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.

Who sold Selecta Biosciences stock? Who is selling Selecta Biosciences stock?

Selecta Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC. Company insiders that have sold Selecta Biosciences company stock in the last year include Amir Nashat, David Siewers, Edwin M Kania, Jr, Lloyd P Johnston and Peter Keller. View Insider Buying and Selling for Selecta Biosciences.

Who bought Selecta Biosciences stock? Who is buying Selecta Biosciences stock?

Selecta Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Earl Sands, Nanodimension Management Ltd, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.

How do I buy Selecta Biosciences stock?

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of Selecta Biosciences stock can currently be purchased for approximately $9.27.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $207.06 million and generates $8.08 million in revenue each year. The company earns $-36,210,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. Selecta Biosciences employs 66 workers across the globe.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]


MarketBeat Community Rating for Selecta Biosciences (SELB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Selecta Biosciences (NASDAQ:SELB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$30.00$28.33
Price Target Upside: 210.83% upside135.01% upside34.65% upside109.72% upside

Selecta Biosciences (NASDAQ:SELB) Consensus Price Target History

Price Target History for Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences (NASDAQ:SELB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Canaccord GenuityReiterated RatingBuy$30.00LowView Rating Details
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00HighView Rating Details
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 -> $32.00N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Selecta Biosciences (NASDAQ:SELB) Earnings History and Estimates Chart

Earnings by Quarter for Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences (NASDAQ SELB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.88)($0.66)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.86)($0.85)$0.03 millionViewN/AView Earnings Details
5/11/2017Q1 2017($1.22)($0.82)$0.14 millionViewN/AView Earnings Details
3/27/201712/31/2016($0.25)($0.77)$15.00 million$2.93 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.48)($0.43)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.45)($2.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Selecta Biosciences (NASDAQ:SELB) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-2.84 EPS

Dividends

Dividend History for Selecta Biosciences (NASDAQ:SELB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Selecta Biosciences (NASDAQ SELB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 54.44%
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences (NASDAQ SELB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2017Earl SandsInsiderBuy7,500$10.26$76,950.007,500View SEC Filing  
11/14/2017Timothy A SpringerDirectorBuy57,598$9.27$533,933.46461,349View SEC Filing  
11/13/2017Werner CautreelsInsiderBuy20,000$9.31$186,200.00321,203View SEC Filing  
11/10/2017Timothy C BarabeDirectorBuy5,000$9.37$46,850.004,992View SEC Filing  
9/26/2017Amir NashatDirectorSell70,226$18.91$1,327,973.66View SEC Filing  
9/25/2017Amir NashatDirectorSell79,211$19.13$1,515,306.43View SEC Filing  
9/21/2017Amir NashatDirectorSell147,187$19.91$2,930,493.17View SEC Filing  
9/20/2017Amir NashatDirectorSell42,610$20.03$853,478.30View SEC Filing  
9/20/2017David SiewersCFOSell16,424$20.00$328,480.002,194View SEC Filing  
7/3/2017Lloyd P JohnstonCOOSell5,959$19.10$113,816.907,565View SEC Filing  
6/30/2017David SiewersCFOSell7,420$20.00$148,400.007,420View SEC Filing  
6/29/2017David SiewersCFOSell9,652$20.00$193,040.003,882View SEC Filing  
6/27/2017Peter KellerInsiderSell4,595$19.30$88,683.505,000View SEC Filing  
6/27/2017Timothy A SpringerDirectorBuy338,791$17.71$5,999,988.61355,413View SEC Filing  
6/26/2017David SiewersCFOSell6,886$20.00$137,720.0036View SEC Filing  
6/15/2017Lloyd P JohnstonCOOSell20,512$17.00$348,704.0022,118View SEC Filing  
6/1/2017Timothy A SpringerDirectorBuy518$13.75$7,122.5016,622View SEC Filing  
5/18/2017Timothy A SpringerDirectorBuy16,104$14.00$225,456.0011,244View SEC Filing  
5/16/2017Edwin M. Kania, Jr.DirectorSell266,795$14.00$3,735,130.00View SEC Filing  
4/17/2017Lloyd P JohnstonCOOSell13,205$13.95$184,209.7514,811View SEC Filing  
12/28/2016Takashi Kei KishimotoInsiderSell10,000$17.55$175,500.0010,000View SEC Filing  
12/21/2016David AbrahamInsiderSell14,844$18.00$267,192.0014,844View SEC Filing  
12/19/2016Peter KellerInsiderSell4,723$18.58$87,753.34View SEC Filing  
6/27/2016Amir NashatDirectorBuy150,000$14.00$2,100,000.00View SEC Filing  
6/27/2016Nanodimension Management LtdMajor ShareholderBuy385,000$14.00$5,390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Selecta Biosciences (NASDAQ SELB) News Headlines

Source:
DateHeadline
Selecta Biosciences (SELB) Rating Reiterated by Canaccord GenuitySelecta Biosciences (SELB) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - January 19 at 12:58 AM
Analyzing Selecta Biosciences (SELB) & Its RivalsAnalyzing Selecta Biosciences (SELB) & Its Rivals
www.americanbankingnews.com - January 16 at 9:26 PM
Comparing Selecta Biosciences (SELB) and Its RivalsComparing Selecta Biosciences (SELB) and Its Rivals
www.americanbankingnews.com - January 16 at 3:10 AM
Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-RapamycinPublication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-Rapamycin
finance.yahoo.com - January 9 at 10:38 AM
Reviewing Selecta Biosciences (SELB) and Its RivalsReviewing Selecta Biosciences (SELB) and Its Rivals
www.americanbankingnews.com - January 6 at 11:52 AM
Selecta Biosciences Inc (NASDAQ:SELB): What’s The Analyst Consensus Outlook?Selecta Biosciences Inc (NASDAQ:SELB): What’s The Analyst Consensus Outlook?
finance.yahoo.com - January 5 at 6:25 PM
Selecta Biosciences Announces CEO’s Intent to Retire and Transition PlanSelecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
finance.yahoo.com - January 2 at 10:36 AM
Selecta Biosciences Inc’s (NASDAQ:SELB) Earnings Declined 44.7%, But How Did It Fare Against The Industry?Selecta Biosciences Inc’s (NASDAQ:SELB) Earnings Declined 44.7%, But How Did It Fare Against The Industry?
finance.yahoo.com - December 28 at 1:44 PM
ETFs with exposure to Selecta Biosciences, Inc. : December 27, 2017ETFs with exposure to Selecta Biosciences, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 4:32 PM
Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 11:20 AM
Head-To-Head Review: Selecta Biosciences (SELB) and Its PeersHead-To-Head Review: Selecta Biosciences (SELB) and Its Peers
www.americanbankingnews.com - December 18 at 7:50 AM
Achillion Pharmaceuticals (ACHN) & Selecta Biosciences (SELB) Critical ComparisonAchillion Pharmaceuticals (ACHN) & Selecta Biosciences (SELB) Critical Comparison
www.americanbankingnews.com - November 29 at 7:30 AM
Selecta Biosciences, Inc. (SELB) Receives Average Rating of "Buy" from AnalystsSelecta Biosciences, Inc. (SELB) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 27 at 5:50 PM
Earl Sands Purchases 7,500 Shares of Selecta Biosciences, Inc. (SELB) StockEarl Sands Purchases 7,500 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - November 21 at 4:41 PM
Insider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of StockInsider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of Stock
www.americanbankingnews.com - November 16 at 8:10 PM
Selecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in StockSelecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in Stock
www.americanbankingnews.com - November 14 at 10:34 PM
Timothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) StockTimothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - November 13 at 7:52 PM
Selecta Biosciences, Inc. (SELB) Upgraded to "Buy" by Zacks Investment ResearchSelecta Biosciences, Inc. (SELB) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 11 at 6:30 AM
Selecta Biosciences Enters Oversold Territory (SELB)Selecta Biosciences Enters Oversold Territory (SELB)
www.thestreet.com - November 9 at 6:13 PM
Edited Transcript of SELB earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of SELB earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 1:12 PM
Selecta Biosciences, Inc. (SELB) Downgraded to "Neutral" at UBS AGSelecta Biosciences, Inc. (SELB) Downgraded to "Neutral" at UBS AG
www.americanbankingnews.com - November 9 at 10:54 AM
Selecta Biosciences (SELB) "Buy" Rating Reiterated at Canaccord GenuitySelecta Biosciences' (SELB) "Buy" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - November 7 at 12:08 PM
Selecta Biosciences, Inc. to Host Earnings CallSelecta Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 10:04 AM
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateSelecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 10:04 AM
Selecta Biosciences, Inc. (SELB) Receives Average Recommendation of "Buy" from AnalystsSelecta Biosciences, Inc. (SELB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 9:44 PM
Selecta Biosciences, Inc. (SELB) Scheduled to Post Quarterly Earnings on WednesdaySelecta Biosciences, Inc. (SELB) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
-$0.88 EPS Expected for Selecta Biosciences, Inc. (SELB) This Quarter-$0.88 EPS Expected for Selecta Biosciences, Inc. (SELB) This Quarter
www.americanbankingnews.com - October 31 at 11:08 PM
Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
feeds.benzinga.com - October 31 at 8:50 AM
Selecta Biosciences Announces Important Additions to Senior Leadership TeamSelecta Biosciences Announces Important Additions to Senior Leadership Team
finance.yahoo.com - October 27 at 5:02 PM
Selecta Biosciences, Inc. (SELB) PT Raised to $30.00Selecta Biosciences, Inc. (SELB) PT Raised to $30.00
www.americanbankingnews.com - October 12 at 10:38 PM
Selecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment ResearchSelecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 12 at 6:20 AM
Selecta Biosciences, Inc. (SELB) Given Consensus Rating of "Hold" by BrokeragesSelecta Biosciences, Inc. (SELB) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 6:38 PM
Selecta Biosciences Announces Upcoming Clinical and Scientific PresentationsSelecta Biosciences Announces Upcoming Clinical and Scientific Presentations
finance.yahoo.com - October 6 at 9:21 AM
Selecta Biosciences, Inc. (SELB) Director Sells $1,327,973.66 in StockSelecta Biosciences, Inc. (SELB) Director Sells $1,327,973.66 in Stock
www.americanbankingnews.com - September 28 at 7:24 PM
Insider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 79,211 Shares of StockInsider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 79,211 Shares of Stock
www.americanbankingnews.com - September 26 at 7:24 PM
David Siewers Sells 16,424 Shares of Selecta Biosciences, Inc. (SELB) StockDavid Siewers Sells 16,424 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - September 22 at 7:52 PM
Insider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 42,610 Shares of StockInsider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 42,610 Shares of Stock
www.americanbankingnews.com - September 22 at 7:32 PM
Selecta Biosciences, Inc. (SELB) Director Sells $2,930,493.17 in StockSelecta Biosciences, Inc. (SELB) Director Sells $2,930,493.17 in Stock
www.americanbankingnews.com - September 22 at 7:30 PM
Selecta Biosciences to Participate in Upcoming Investor ConferencesSelecta Biosciences to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 20 at 8:54 AM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017
finance.yahoo.com - September 14 at 9:53 AM
Selecta Biosciences, Inc. (SELB) Receives Consensus Rating of "Buy" from AnalystsSelecta Biosciences, Inc. (SELB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 8:54 PM
Selecta Biosciences, Inc. (SELB) Expected to Announce Earnings of -$0.88 Per ShareSelecta Biosciences, Inc. (SELB) Expected to Announce Earnings of -$0.88 Per Share
www.americanbankingnews.com - September 5 at 2:14 PM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 12:33 PM
Selecta Biosciences, Inc. (SELB) Given Consensus Recommendation of "Buy" by BrokeragesSelecta Biosciences, Inc. (SELB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 19 at 6:50 PM
Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017
finance.yahoo.com - August 15 at 9:32 PM
Selecta Biosciences, Inc. (NASDAQ:SELB) Issues Quarterly  Earnings ResultsSelecta Biosciences, Inc. (NASDAQ:SELB) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 12 at 10:40 AM
Edited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMTEdited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 12 at 7:44 AM
Selecta Biosciences (NASDAQ:SELB) Buy Rating Reaffirmed at Canaccord GenuitySelecta Biosciences' (NASDAQ:SELB) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 11 at 6:20 PM

SEC Filings

Selecta Biosciences (NASDAQ:SELB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Selecta Biosciences (NASDAQ:SELB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Selecta Biosciences (NASDAQ SELB) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.